Laura Kennedy is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 79 publications with 1,641 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372324405
Telephone
615-936-2000Provider last certified this registry record 19 Sept 2023.
Clinical trials
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Sponsor: Vanderbilt-Ingram Cancer Center
- Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment
Sponsor: Laura Kennedy
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.8%Aromatase Inhibitor38.4%Letrozole83%Exemestane10%Anastrozole7%Part D<11 patientsKinase inhibitor29%Verzenio43%Kisqali28%Ibrance19%Tukysa10%Part D<11 patients+ 1 more class in this area
Nervous system
12.3%Phenothiazine6.4%Prochlorperazine Maleate100%Part D≥13 patientsGabapentinoids3.9%Gabapentin100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
11.3%Serotonin-3 Receptor Antagonist8%Ondansetron Hcl100%Part D≥20 patientsH2 blocker3.3%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2025$578,023R01CA273246 - Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2024$546,296R01CA273246 - Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2023$510,310R01CA273246
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
William Schaffner, MD
Vanderbilt University
Keith Obstein, MD, MPH
Vanderbilt University
Andrew Jallouk, MD, PhD
Vanderbilt University
Salim Yusuf
Vanderbilt University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”